Douglas Dalke
Family · San Antonio, TXNPI 1104507656
Payments from drug & device makers
Across 509 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Ascensia Diabetes Care US Inc.$939
- Novo Nordisk$892
- Boehringer Ingelheim$811
- Senseonics, Incorporated$800
- Corcept Therapeutics$696
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$8009%
- Food & beverage$8,49191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 70 | $1,371 |
| Ascensia Diabetes Care US Inc. | 74 | $939 |
| Novo Nordisk | 47 | $892 |
| Boehringer Ingelheim | 44 | $811 |
| Senseonics, Incorporated | 2 | $800 |
| Corcept Therapeutics | 29 | $696 |
| Amgen | 30 | $458 |
| Mannkind Corporation | 41 | $413 |
| Kyowa Kirin, Inc. | 16 | $385 |
| Novartis | 22 | $374 |
| Radius Health, Inc. | 22 | $353 |
| Sequel Med Tech, LLC | 35 | $299 |
| Recordati_rare_diseases_inc. | 17 | $291 |
| Bayer | 13 | $227 |
| Soleno Therapeutics, Inc. | 6 | $163 |
| Cequr Corporation | 3 | $132 |
| Insulet Corporation | 7 | $122 |
| Madrigal Pharmaceuticals | 5 | $112 |
| AstraZeneca | 6 | $90 |
| Xeris Pharmaceuticals, Inc. | 4 | $72 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Averitas Pharma Inc. | 2 | $34 |
| AbbVie | 2 | $33 |
| Rhythm Pharmaceuticals, Inc. | 1 | $32 |
| Pfizer | 2 | $28 |
| BETA Bionics, Inc. | 2 | $26 |
| Almatica Pharma LLC | 1 | $22 |
| Chiesi USA, Inc. | 1 | $22 |
| GSK | 1 | $21 |
| Medtronic | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,291 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 19 | $761,503 |
| OzempicSemaglutide | 169 | $191,854 |
| MounjaroTirzepatide | 160 | $183,596 |
| AfrezzaInsulin Regular, Human | 42 | $101,708 |
| JardianceEmpagliflozin | 37 | $48,341 |
| TymlosAbaloparatide | 13 | $34,671 |
| TrulicityDulaglutide | 26 | $31,438 |
| ProliaDenosumab | 14 | $24,493 |
| FarxigaDapagliflozin Propanediol | 16 | $20,847 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $16,715 |
| V-Go 30Sub-Q Insulin Device, 30 Unit | 22 | $13,602 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $11,477 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 20 | $10,490 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $10,242 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $6,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $696 | $761,50319 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,371 | $215,033186 claims |
| Novo NordiskOzempic | $892 | $191,854169 claims |
| Mannkind CorporationAfrezza | $413 | $101,70842 claims |
| Boehringer IngelheimJardiance | $811 | $48,34137 claims |
| Radius Health, Inc.Tymlos | $353 | $34,67113 claims |
| AmgenProlia | $458 | $24,49314 claims |
| AstraZenecaFarxiga | $90 | $20,84716 claims |
| AbbVieSynthroid | $33 | $1,28816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.